AI Colposcopy Aid Shows High Accuracy, Triage Evidence LagsAI Tools Show Promise in Cervical Cancer Screening and Triage
Current opinion in oncologyPublished September 1, 2026Study authors: Cengiz Murat, Zaim Onur Can, Temiz Bilal Esat, Grigore Mihaela, Gultekin MuratPubMed ↗DOI ↗Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
AI colposcopy assistance is most clinically ready, but triage of hrHPV-positive women needs stronger evidence.
A comprehensive meta-analysis evaluated artificial intelligence (AI) tools for cervical cancer screening and triage, analyzing 97 eligible studies, with 47 providing reconstructible 2x2 data. The evidence was strongest for AI as a diagnostic aid during colposcopy, where it achieved an area under the curve (AUC) of 0.94, with a pooled sensitivity of 0.908 and specificity of 0.844 across 21 studies. This suggests AI can effectively assist clinicians in identifying lesions during colposcopic examination.
For primary AI-cytology screening, the pooled AUC was 0.92, with high sensitivity (0.934) but unstable specificity (0.701, 95% CI 0.460-0.865) across 10 studies. This variability raises concerns about its reliability as a standalone screening tool, potentially leading to unnecessary referrals or missed cases.
The weakest evidence was for AI in triage of hrHPV-positive women, with only 4 studies and a sensitivity of 0.805 (95% CI lower bound 0.624), falling below the 90% safety threshold. This is a critical gap, as effective triage is essential to avoid overtreatment and reduce unnecessary procedures.
Publication bias was significant for diagnostic assistance (Deeks' funnel asymmetry P=0.007) and borderline for screening (P=0.082), indicating that positive results may be overrepresented. Additionally, only 10.9% of studies performed external validation, limiting generalizability.
In summary, AI shows promise as a colposcopy aid, but its role in primary screening and triage requires further robust research, particularly for hrHPV-positive women.
How this fits prior evidence
This meta-analysis extends prior coverage on cervical cancer screening by quantifying AI accuracy across different clinical roles. It confirms the potential of AI as a diagnostic aid during colposcopy, aligning with prior findings on technological opportunities to improve cervical cancer care access. It also addresses a gap by highlighting the weak evidence for AI in triage of hrHPV-positive women, which is critical for post-screening management. The unstable specificity of AI-cytology screening contrasts with the reassuring single-dose HPV vaccine results noted earlier, underscoring that screening accuracy remains a challenge.
Researchers analyzed 97 studies to see how artificial intelligence (AI) performs in cervical cancer screening and triage. The review looked at how well AI can identify cancer in different stages, including initial cytology screening and the triage of women who test positive for high-risk HPV.
The findings show that AI is most effective and reliable when used as a diagnostic assistant during colposcopy, with a high accuracy score. However, AI used for initial cytology screening showed high sensitivity but had inconsistent results for specificity. The data for AI used in triage for high-risk HPV patients was the smallest and weakest group of studies, meaning there is less certainty about its performance in that specific area.
Because many studies lacked external validation, the evidence is not yet complete. While AI shows potential as a tool to help doctors, it is not yet a replacement for clinical judgment. Patients should discuss these emerging technologies with their healthcare providers to understand how they might fit into standard care.
What this means for you:
AI shows high accuracy in some cervical cancer screening steps, but evidence is still limited in others.
Common questions
How accurate is AI in cervical cancer screening?
AI shows high accuracy when used as a diagnostic assistant during colposcopy, with a reported area under the curve of 0.94. However, its accuracy in other areas varies. For example, AI used in primary cytology screening had high sensitivity but showed unstable specificity.
Is AI ready to replace human doctors in cervical cancer triage?
The evidence is not yet sufficient to replace human judgment. While AI shows promise as a diagnostic assistant, the data for triage of high-risk HPV-positive women is currently the smallest and weakest pool of evidence, meaning more research is needed.
What are the limitations of using AI for these screenings?
A major limitation is the low rate of external validation, which was only 10.9% of the studies. Additionally, the evidence for triage of high-risk HPV-positive women is currently considered weak and falls below certain safety thresholds for certainty.
PURPOSE OF REVIEW: Artificial intelligence (AI) tools for cervical cancer screening have proliferated, but modality-pooled accuracy estimates conflate clinically distinct uses of AI. We re-examine this evidence base through a role-stratified bivariate meta-analysis to clarify where AI is ready for clinical translation and where gaps remain.
RECENT FINDINGS: Of 97 eligible studies published between 2019 and 2026, 47 with reconstructible 2 × 2 data were pooled using a bivariate Reitsma model stratified by clinical role. Diagnostic assistance during colposcopy showed the most mature evidence ( k = 21; sensitivity 0.908, specificity 0.844; HSROC AUC 0.94). Primary AI-cytology screening showed high sensitivity but unstable specificity ( k = 10; 0.934/0.701 [0.460-0.865]; AUC 0.92). Triage of hrHPV-positive women was the smallest and weakest pool ( k = 4; sensitivity 0.805, 95% CI lower bound 0.624 - below the 90% safety threshold commonly cited for HPV-positive triage). External validation was reported in 10.9% of studies and 49.1% originated from China. Deeks' funnel asymmetry was borderline for screening ( P = 0.082) and significant for diagnostic assistance ( P = 0.007).
SUMMARY: AI is closest to translation as diagnostic assistance during colposcopy. PosthrHPV triage - not primary screening - is the critical evidence gap. Future work should prioritize prospective multicentre multimodal (HPV + AI cytology + orthogonal biomarker) risk-calibrated triage models over further modality-pooled accuracy studies.
